4.7 Article

microRNA-874 suppresses tumor proliferation and metastasis in hepatocellular carcinoma by targeting the DOR/EGFR/ERK pathway

期刊

CELL DEATH & DISEASE
卷 9, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41419-017-0131-3

关键词

-

资金

  1. National Natural Science Foundation of China [81702435, 81360367, 81560393]
  2. Natural Science Foundation of Jiangsu [BK20170264]
  3. Natural Science Foundation of Guangxi [2015jjDA40010]
  4. Guangxi Science Fund for Distinguished Young Scholars Program [2016GXNSFFA380003]
  5. Scientific Research and Technology Development Project for Guilin [20140310-2-2]
  6. Guangxi Regional High-risk Tumors Early Prevention, and Control of Key Laboratory Open Research Project [GK2014-TKF01]

向作者/读者索取更多资源

The delta opioid receptor (DOR) is involved in the regulation of malignant transformation and tumor progression of hepatocellular carcinoma (HCC). However, regulation of the DOR in HCC remains poorly defined. We found that miR-874 was identified as a negative regulator of the DOR, which is a direct and functional target of miR-874 via its 3' untranslated region (UTR). Moreover, miR-874 was downregulated in HCC and its expression was inversely correlated with DOR expression. Downregulation of miR-874 was also associated with larger tumor size, more vascular invasion, a poor TNM stage, poor tumor differentiation, and inferior patient outcomes. Functionally, overexpression of miR-874 in the HCC cell line SK-hep-1 inhibited cell growth, migration, in vitro invasion, and in vivo tumorigenicity. Furthermore, miR-874 overexpression suppressed the DOR, resulting in a downregulated epidermal growth factor receptor (EGFR) and extracellular signal-regulated kinase (ERK) phosphorylation. The EGFR activator-epidermal growth factor (EGF)-can rescue the proliferation and migration suppression induced by miR-874 overexpression, and the rescue effects of the EGF were blocked by an ERK inhibitor. Our study results suggest that miRNA-874 is a negative regulator of the DOR that can suppress tumor proliferation and metastasis in HCC by targeting the DOR/EGFR/ERK pathway, which may be a potential target for HCC treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据